Search Result

Results for "

cerebral infarction

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Acyltransferase (1) Apoptosis (1) Chloride Channel (1) Complement System (1) Endothelin Receptor (1) iGluR (1) Isotope-Labeled Compounds (1) mAChR (2) Phosphodiesterase (PDE) (2)
By Research Areas:	Cancer (2) Cardiovascular Disease (6) Inflammation/Immunology (1) Metabolic Disease (1) Neurological Disease (8)

Inhibitors & Agonists

Peptides

Inhibitory Antibodies

Natural
Products

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-153595

DAPK-IN-2

Others Cardiovascular Disease

DAPK-IN-2 is a DAPK inhibitor. DAPK-IN-2 can be used for the research of cerebral infarction and ischemic diseases .

DAPK-IN-2	Others	Cardiovascular Disease
DAPK-IN-2 is a DAPK inhibitor. DAPK-IN-2 can be used for the research of cerebral infarction and ischemic diseases .

HY-17352

Clazosentan Ro 61-1790; VML 588; AXV-034343	Endothelin Receptor	Cardiovascular Disease
Clazosentan (Ro 61-1790) is a selective endothelin A (ET_A) receptor antagonist. Clazosentan inhibits ET-1-mediated vasoconstriction. Clazosentan prevents cerebral vasospasm, vasospasm-related cerebral infarction .

HY-103479

GOAT-IN-1	Acyltransferase	Cardiovascular Disease Neurological Disease Metabolic Disease Cancer
GOAT-IN-1 is an inhibitor of ghrelin O-acyltransferase (GOAT), which could be useful for the prophylaxis or treatment of obesity, diabetes, hyperlipidemia, metabolic, non-alcoholic fatty liver, steatohepatitis, sarcopenia, appetite control, alcohol/narcotic dependence, Alzheimer’s disease, Parkinson’s disease, cerebrovascular dementia, cerebral apoplexy, cerebral infarction, cardic disease, some kind of tumors.

HY-133712

Yonkenafil Tunodafil	Phosphodiesterase (PDE)	Neurological Disease
Yonkenafil (Tunodafil), a novel phosphodiesterase 5 (PDE5) inhibitor, is effective in reducing cerebral infarction, neurological deficits, edema, and neuronal damage in the infarcted area. Yonkenafil may improve cognitive function by modulating neurogenesis and has a potential therapeutic effect on Alzheimer's disease .

HY-P99886

Pexelizumab h5G1. 1-SC	Complement System Apoptosis	Cardiovascular Disease Neurological Disease
Pexelizumab (h5G1. 1-SC) is a humanized scFv monoclonal antibody directed against the C5 complement component. Pexelizumab inhibits apoptosis and leukocyte infiltration. Pexelizumab can be used for the research of cerebral IR injury and myocardial infarction .

HY-125095

Yonkenafil hydrochloride Tunodafil hydrochloride	Phosphodiesterase (PDE)	Cardiovascular Disease Neurological Disease
Yonkenafil (Tunodafil) hydrochloride, a novel phosphodiesterase 5 (PDE5) inhibitor, is effective in reducing cerebral infarction, neurological deficits, edema, and neuronal damage in the infarcted area. Yonkenafil (Tunodafil) hydrochloride may improve cognitive function by modulating neurogenesis and has a potential therapeutic effect on Alzheimer's disease .

HY-107802

Breviscapine Breviscapinun	Others	Cardiovascular Disease
Breviscapine is a crude flavonoid extract of Breviscapine, which is more than 85% of the active ingredient, Breviscapine. Breviscapine has a wide range of cardiovascular pharmacological activities, such as increasing blood flow, improving microcirculation, dilating blood vessels, reducing blood viscosity, promoting fibrinolysis, inhibiting platelet aggregation and thrombosis. Breviscapine has been used in the study of cerebral infarction and its sequelae, cerebral thrombosis, coronary heart disease and angina pectoris .

HY-76569

Desfesoterodine PNU-200577; 5-Hydroxymethyl Tolterodine	mAChR	Neurological Disease
Desfesoterodine (PNU-200577) is a potent and selective muscarinic receptor (mAChR) antagonist with a K_B and a pA₂ of 0.84 nM and 9.14, respectively . Desfesoterodine is a major pharmacologically active metabolite of Tolterodine (PNU-200583; HY-A0024) and Fesoterodine (HY-70053) . Desfesoterodine improves cerebral infarction induced detrusor overactivity in rats .

HY-100611

CaCCinh-A01 4 Publications Verification	Chloride Channel	Inflammation/Immunology Cancer
CaCCinh-A01 is an inhibitor of both TMEM16A and calcium-activated chloride channel (CaCC) with IC₅₀s of 2.1 and 10 μM, respectively.

HY-76569S1

(R)-Hydroxytolterodine-d14 PNU-200577-d₁₄; 5-Hydroxymethyl Tolterodine-d₁₄	mAChR Isotope-Labeled Compounds	Neurological Disease
(R)-Hydroxytolterodine-d₁₄ is deuterated labeled Desfesoterodine (HY-76569). Desfesoterodine (PNU-200577) is a potent and selective muscarinic receptor (mAChR) antagonist with a K_B and a pA₂ of 0.84 nM and 9.14, respectively . Desfesoterodine is a major pharmacologically active metabolite of Tolterodine (PNU-200583; HY-A0024) and Fesoterodine (HY-70053) . Desfesoterodine improves cerebral infarction induced detrusor overactivity in rats .

HY-157936

GluN2B-NMDAR antagonist-2	iGluR	Neurological Disease
GluN2B-NMDAR antagonist-2 (compound S-58) is a potent, selective and cross the blood-brain barrier NMDAR-GluN2B antagonist with an IC₅₀ value of 74.01, nM. GluN2B-NMDAR antagonist-2 shows mild cytotoxicity. GluN2B-NMDAR antagonist-2 decreases the cerebral infarction rates and neurologic deficit scores. GluN2B-NMDAR antagonist-2 has the potential for the research of stroke .

Tat-NTS peptide	Peptides	Neurological Disease
Tat-NTS peptide is a cell-penetrating peptide with neuroprotective effects. Tat-NTS peptide can specifically inhibit the nuclear translocation of ANXA1 and reduce neuronal apoptosis in ischemic areas. Moreover, Tat-NTS peptide can reduce the volume of cerebral ischemic infarction and can be used in the research of ischemic stroke .

Pexelizumab h5G1. 1-SC	Complement System Apoptosis	Cardiovascular Disease Neurological Disease
Pexelizumab (h5G1. 1-SC) is a humanized scFv monoclonal antibody directed against the C5 complement component. Pexelizumab inhibits apoptosis and leukocyte infiltration. Pexelizumab can be used for the research of cerebral IR injury and myocardial infarction .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-107802

Breviscapine Breviscapinun	Structural Classification Natural Products Source classification Plants Compositae Erigeron breviscapus (Vant.) Hand.-Mazz.	Others
Breviscapine is a crude flavonoid extract of Breviscapine, which is more than 85% of the active ingredient, Breviscapine. Breviscapine has a wide range of cardiovascular pharmacological activities, such as increasing blood flow, improving microcirculation, dilating blood vessels, reducing blood viscosity, promoting fibrinolysis, inhibiting platelet aggregation and thrombosis. Breviscapine has been used in the study of cerebral infarction and its sequelae, cerebral thrombosis, coronary heart disease and angina pectoris .

Cat. No.	Product Name	Chemical Structure

HY-76569S1

(R)-Hydroxytolterodine-d14
(R)-Hydroxytolterodine-d₁₄ is deuterated labeled Desfesoterodine (HY-76569). Desfesoterodine (PNU-200577) is a potent and selective muscarinic receptor (mAChR) antagonist with a K_B and a pA₂ of 0.84 nM and 9.14, respectively . Desfesoterodine is a major pharmacologically active metabolite of Tolterodine (PNU-200583; HY-A0024) and Fesoterodine (HY-70053) . Desfesoterodine improves cerebral infarction induced detrusor overactivity in rats .

(R)-Hydroxytolterodine-d14

(R)-Hydroxytolterodine-d₁₄ is deuterated labeled Desfesoterodine (HY-76569). Desfesoterodine (PNU-200577) is a potent and selective muscarinic receptor (mAChR) antagonist with a K_B and a pA₂ of 0.84 nM and 9.14, respectively . Desfesoterodine is a major pharmacologically active metabolite of Tolterodine (PNU-200583; HY-A0024) and Fesoterodine (HY-70053) . Desfesoterodine improves cerebral infarction induced detrusor overactivity in rats .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks